Comparison of Her2 and Ki67 as Prognostic Markers in Colorectal Cancer

Intervention1: Immunohistochemistry: Application of Immunohistochemical markers like Her2 and Ki67 on paraffin blocks of resected specimen of colorectal carcinoma patients for the duration or till the desired sample size is achieved, whichever is earlier.
Control Intervention1: NIL: NIL
Primary outcome(s): Prognostication of Her2 and Ki67 in colorectal Carcinoma patients.Timepoint: Primary outcome is expected to be achieved by the end of 2 years.
Study Design: Other Method of generating randomization sequence: Method of allocation concealment: Blinding and masking:

干预措施1：免疫组织化学（Immunohistochemistry）：针对结直肠癌患者切除标本的石蜡包埋块，应用Her2、Ki67等免疫组织化学标志物开展检测，直至达到预设样本量或试验周期结束，以先到者为准。
对照干预措施1：无干预（NIL）：无干预
主要结局指标：结直肠癌患者中Her2与Ki67的预后评估。时间节点：主要结局指标预计于2年末达成。
试验设计：随机序列生成方法： 分配隐藏方法： 设盲与设掩：